Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-PD-L1 monoclonal antibody (human)
- Development stage
- Unknown
- Lead developer
- SET Technology
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, RNA Therapeutics → Nucleic Acid Therapeutics, DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular, Intravenous
01
Overview
INVIVO-mAb Anti PDL-1 is an innovative in vivo monoclonal antibody therapy being developed by SET Technology for the treatment of various cancers. Utilizing a proprietary DNA/RNA-based delivery platform, the therapy delivers the genetic instructions for a human anti-PD-L1 monoclonal antibody directly into the patient's cells. This allows the patient's own body to serve as a bioreactor, producing the therapeutic antibody internally to achieve sustained immune checkpoint blockade. By targeting the Programmed cell death 1 ligand 1 (PD-L1), the antibody prevents its interaction with the PD-1 receptor on T cells, thereby reversing tumor-mediated immunosuppression and enhancing the anti-tumor immune response. The program is currently in Phase 1 clinical development for melanoma and in the optimization stage for other oncology indications including sarcoma and breast cancer.
- Other names
- anti-PD-L1 monoclonal antibody (human)in vivo monoclonal antibody (DNA/RNA-based)
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on anti-PD-L1 monoclonal antibody (human).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-PD-L1 monoclonal antibody (human).